Broad Neutralization by a Combination of Antibodies Recognizing the CD4 Binding Site and a New Conformational Epitope on the HIV-1 Envelope Protein

View/ Open
Author
Klein, Florian
Gaebler, Christian
Mouquet, Hugo
Sather, D. Noah
Lehmann, Clara
Scheid, Johannes F.
Kraft, Zane
Liu, Yan
Pietzsch, John
Hurley, Arlene
Poignard, Pascal
Feizi, Ten
Morris, Lynn
Fätkenheuer, Gerd
Stamatatos, Leonidas
Nussenzweig, Michel C.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1084/jem.20120423Metadata
Show full item recordCitation
Klein, Florian, Christian Gaebler, Hugo Mouquet, D. Noah Sather, Clara Lehmann, Johannes F. Scheid, Zane Kraft, et al. 2012. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. The Journal of Experimental Medicine 209(8): 1469-1479.Abstract
Two to three years after infection, a fraction of HIV-1–infected individuals develop serologic activity that neutralizes most viral isolates. Broadly neutralizing antibodies that recognize the HIV-1 envelope protein have been isolated from these patients by single-cell sorting and by neutralization screens. Here, we report a new method for anti–HIV-1 antibody isolation based on capturing single B cells that recognize the HIV-1 envelope protein expressed on the surface of transfected cells. Although far less efficient than soluble protein baits, the cell-based capture method identified antibodies that bind to a new broadly neutralizing epitope in the vicinity of the V3 loop and the CD4-induced site (CD4i). The new epitope is expressed on the cell surface form of the HIV-1 spike, but not on soluble forms of the same envelope protein. Moreover, the new antibodies complement the neutralization spectrum of potent broadly neutralizing anti-CD4 binding site (CD4bs) antibodies obtained from the same individual. Thus, combinations of potent broadly neutralizing antibodies with complementary activity can account for the breadth and potency of naturally arising anti–HIV-1 serologic activity. Therefore, vaccines aimed at eliciting anti–HIV-1 serologic breadth and potency should not be limited to single epitopes.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409500/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:10611742
Collections
- HMS Scholarly Articles [17842]
Contact administrator regarding this item (to report mistakes or request changes)